OpenAI, xAI, and Anthropic are no longer operating in the dark when it comes to investor visibility. Morningstar just launched a new daily index that tracks 20 OpenAI, xAI, and Anthropic are no longer operating in the dark when it comes to investor visibility. Morningstar just launched a new daily index that tracks 20

Morningstar unveils index tracking private GenAI firms OpenAI, xAI, Anthropic, others

OpenAI, xAI, and Anthropic are no longer operating in the dark when it comes to investor visibility. Morningstar just launched a new daily index that tracks 20 generative AI companies, including these three, giving investors their first actual shot at measuring performance in a space that’s been closed off for too long.

The index pulls data from PitchBook, a private market tracker Morningstar bought back in 2016. That’s the engine behind it.

Lots of the biggest and fastest-growing AI companies don’t trade publicly. They stay private and don’t show their books unless you’re already in the club. So investors who aren’t already inside have had zero clarity.

Public markets don’t tell the story anymore, and that’s what Morningstar says it wants to fix. “You can’t really understand the future of AI by looking at public markets,” said Sanjay Arya, head of innovation for Morningstar’s index business. “So you have to create something which completes the picture.”

Morningstar tracks GenAI companies using private data

Morningstar’s new tool is meant to publish daily updates tracking valuation changes across 20 GenAI companies, based on funding rounds and revaluations with updates coming from PitchBook’s data.

The point is to show how the sector is moving, even when these companies don’t report anything publicly.

Sanjay said one major tech company is already planning to use the index to benchmark its own investments, though he wouldn’t say which one for reasons we do not know.

The index also includes Databricks, Mistral AI, and Cohere.

This isn’t Morningstar’s first foray into private markets either. It’s already running another index that tracks 20 late-stage VC-backed companies with $1 billion+ valuations.

By the end of 2025, almost half of all Index Industry Association members, including MSCI and S&P Dow Jones, had all either launched or announced their own private market indexes.

Sanjay also said that GenAI companies are raising funds more often than they used to. Which means their valuations are changing more often, too.

“If this is going to be a huge part of the economy, I guess you want to see how this segment of the market is growing,” Sanjay explained.

OpenAI and Anthropic target the same market yet again; healthcare

While Morningstar tracks the financial side, OpenAI and Anthropic are getting deep into healthcare. On Thursday, OpenAI said it’s launching a new version of ChatGPT made for clinicians. It’s supposed to help with medical case reviews, tailored care, and cutting down admin work.

The tool comes with citations from verified medical sources and follows HIPAA rules for handling private health data. The rollout has already started at places like Boston Children’s Hospital, Memorial Sloan Kettering, and Cedars-Sinai.

The day before that, OpenAI launched ChatGPT Health, which lets regular users analyze medical tests, prep for doctor visits, and get input on workouts or diets. It’s not a substitute for real doctors, but the idea is to be a helpful add-on. It shows a clear effort by OpenAI to push their product deeper into everyday use and into sectors that deal with personal data.

Anthropic, led by a former biophysicist, is also doubling down on this area. The company rolled out updates to its Claude chatbot, aiming to speed up scientific research. It’s even holding an event next week focused entirely on its health care strategy. Top execs will lay out where they’re heading.

The smartest crypto minds already read our newsletter. Want in? Join them.

Market Opportunity
Index Cooperative Logo
Index Cooperative Price(INDEX)
$0.5339
$0.5339$0.5339
+5.26%
USD
Index Cooperative (INDEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23